Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
The Pharma Data
JULY 27, 2021
Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. executive vice president of Research and Development at Amgen. Reese, M.D.,
Let's personalize your content